vs

Side-by-side financial comparison of Legacy Education Inc. (LGCY) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $19.2M, roughly 1.9× Legacy Education Inc.). Legacy Education Inc. runs the higher net margin — 10.6% vs -304.2%, a 314.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 40.7%). Legacy Education Inc. produced more free cash flow last quarter ($512.7K vs $-47.3M).

Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

LGCY vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.9× larger
RXRX
$35.5M
$19.2M
LGCY
Growing faster (revenue YoY)
RXRX
RXRX
+641.0% gap
RXRX
681.7%
40.7%
LGCY
Higher net margin
LGCY
LGCY
314.9% more per $
LGCY
10.6%
-304.2%
RXRX
More free cash flow
LGCY
LGCY
$47.8M more FCF
LGCY
$512.7K
$-47.3M
RXRX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
LGCY
LGCY
RXRX
RXRX
Revenue
$19.2M
$35.5M
Net Profit
$2.0M
$-108.1M
Gross Margin
59.8%
Operating Margin
13.3%
-304.8%
Net Margin
10.6%
-304.2%
Revenue YoY
40.7%
681.7%
Net Profit YoY
46.0%
39.6%
EPS (diluted)
$0.15
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGCY
LGCY
RXRX
RXRX
Q4 25
$19.2M
$35.5M
Q3 25
$19.4M
$5.2M
Q2 25
$18.0M
$19.2M
Q1 25
$18.6M
$14.7M
Q4 24
$13.6M
$4.5M
Q3 24
$14.0M
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
LGCY
LGCY
RXRX
RXRX
Q4 25
$2.0M
$-108.1M
Q3 25
$2.2M
$-162.3M
Q2 25
$1.2M
$-171.9M
Q1 25
$2.8M
$-202.5M
Q4 24
$1.4M
$-178.9M
Q3 24
$2.1M
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
LGCY
LGCY
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
LGCY
LGCY
RXRX
RXRX
Q4 25
13.3%
-304.8%
Q3 25
13.9%
-3327.6%
Q2 25
11.1%
-916.8%
Q1 25
19.7%
-1297.9%
Q4 24
12.2%
-4042.4%
Q3 24
19.1%
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
LGCY
LGCY
RXRX
RXRX
Q4 25
10.6%
-304.2%
Q3 25
11.3%
-3135.3%
Q2 25
6.8%
-894.2%
Q1 25
15.2%
-1373.3%
Q4 24
10.3%
-3935.5%
Q3 24
14.9%
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
LGCY
LGCY
RXRX
RXRX
Q4 25
$0.15
$-0.17
Q3 25
$0.16
$-0.36
Q2 25
$0.07
$-0.41
Q1 25
$0.21
$-0.50
Q4 24
$0.10
$-0.56
Q3 24
$0.21
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGCY
LGCY
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$21.1M
$743.3M
Total DebtLower is stronger
$660.3K
$9.6M
Stockholders' EquityBook value
$46.1M
$1.1B
Total Assets
$73.1M
$1.5B
Debt / EquityLower = less leverage
0.01×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGCY
LGCY
RXRX
RXRX
Q4 25
$21.1M
$743.3M
Q3 25
$20.6M
$659.8M
Q2 25
$20.3M
$525.1M
Q1 25
$17.3M
$500.5M
Q4 24
$16.9M
$594.4M
Q3 24
$21.5M
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
LGCY
LGCY
RXRX
RXRX
Q4 25
$660.3K
$9.6M
Q3 25
$776.9K
$11.9M
Q2 25
$1.4M
$14.2M
Q1 25
$1.0M
$16.4M
Q4 24
$1.1M
$19.0M
Q3 24
$758.2K
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
LGCY
LGCY
RXRX
RXRX
Q4 25
$46.1M
$1.1B
Q3 25
$43.7M
$1.0B
Q2 25
$41.0M
$919.1M
Q1 25
$39.3M
$933.9M
Q4 24
$36.4M
$1.0B
Q3 24
$32.6M
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
LGCY
LGCY
RXRX
RXRX
Q4 25
$73.1M
$1.5B
Q3 25
$72.1M
$1.4B
Q2 25
$69.2M
$1.3B
Q1 25
$67.1M
$1.3B
Q4 24
$62.1M
$1.4B
Q3 24
$50.6M
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
LGCY
LGCY
RXRX
RXRX
Q4 25
0.01×
0.01×
Q3 25
0.02×
0.01×
Q2 25
0.03×
0.02×
Q1 25
0.03×
0.02×
Q4 24
0.03×
0.02×
Q3 24
0.02×
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGCY
LGCY
RXRX
RXRX
Operating Cash FlowLast quarter
$1.1M
$-46.1M
Free Cash FlowOCF − Capex
$512.7K
$-47.3M
FCF MarginFCF / Revenue
2.7%
-133.1%
Capex IntensityCapex / Revenue
2.8%
3.5%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$4.8M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGCY
LGCY
RXRX
RXRX
Q4 25
$1.1M
$-46.1M
Q3 25
$1.1M
$-117.4M
Q2 25
$3.0M
$-76.4M
Q1 25
$918.7K
$-132.0M
Q4 24
$659.0K
$-115.4M
Q3 24
$3.2M
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
LGCY
LGCY
RXRX
RXRX
Q4 25
$512.7K
$-47.3M
Q3 25
$809.7K
$-117.6M
Q2 25
$2.9M
$-79.6M
Q1 25
$596.6K
$-133.8M
Q4 24
$466.8K
$-116.7M
Q3 24
$2.9M
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
LGCY
LGCY
RXRX
RXRX
Q4 25
2.7%
-133.1%
Q3 25
4.2%
-2272.5%
Q2 25
16.2%
-413.9%
Q1 25
3.2%
-907.4%
Q4 24
3.4%
-2567.7%
Q3 24
21.1%
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
LGCY
LGCY
RXRX
RXRX
Q4 25
2.8%
3.5%
Q3 25
1.3%
4.7%
Q2 25
0.5%
16.4%
Q1 25
1.7%
12.4%
Q4 24
1.4%
28.6%
Q3 24
1.7%
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
LGCY
LGCY
RXRX
RXRX
Q4 25
0.52×
Q3 25
0.48×
Q2 25
2.45×
Q1 25
0.33×
Q4 24
0.47×
Q3 24
1.52×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons